{"id":"NCT00811941","sponsor":"H. Lundbeck A/S","briefTitle":"Safety and Efficacy of Nalmefene in Patients With Alcohol Dependence","officialTitle":"A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Safety, Tolerability and Efficacy Study of Nalmefene, as Needed Use, in Patients With Alcohol Dependence","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-03","primaryCompletion":"2010-11","completion":"2010-11","firstPosted":"2008-12-19","resultsPosted":"2013-08-07","lastUpdate":"2013-08-07"},"enrollment":665,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Alcohol Dependence"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Nalmefene","otherNames":["Selincroâ„¢"]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Nalmefene","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is long-term safety, tolerability and efficacy of nalmefene in patients with alcohol dependence.","primaryOutcome":{"measure":"Number of Patients With Adverse Events (AEs)","timeFrame":"Serious Adverse Events: 52 weeks and a safety follow-up (visit/telephone call) scheduled for 4 weeks after completion of the study or after withdrawal from the study. Other Adverse Events: 52 weeks.","effectByArm":[{"arm":"Placebo","deltaMin":103,"sd":null},{"arm":"Nalmefene 18.06 mg","deltaMin":377,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":60,"countries":["Czechia","Estonia","Hungary","Latvia","Lithuania","Poland","Russia","Slovakia","Ukraine","United Kingdom"]},"refs":{"pmids":["25227627"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":164},"commonTop":["Nausea","Insomnia","Dizziness","Headache","Nasopharyngitis"]}}